Open AccessTreatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
Author(s) -
Yanxia Li,
Nelusha Amaladas,
Marguerita O’Mahony,
Jason R. Manro,
Ivan Inigo,
Qi Li,
Erik Rasmussen,
Manisha Brahmachary,
Thompson N. Doman,
Gerald E. Hall,
Michael Kalos,
Ruslan D. Novosiadly,
Óscar Puig,
Bronislaw Pytowski,
David Schaer
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0268244
Subject(s) - blockade , immune checkpoint , tumor microenvironment , medicine , cancer research , pembrolizumab , immune system , immunotherapy , pd l1 , combination therapy , antibody , angiogenesis , immunology , pharmacology , receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom